Background <p>Glioblastoma is an aggressive tumor with poor prognosis and limited treatment options due to its resistance to chemotherapy and radiotherapy, high heterogeneity, and ability to evade the immune system. Nevertheless, immunotherapy and oncolytic virotherapy are emerging as promising strategies. This study aimed to evaluate the therapeutic efficacy of an engineered oncolytic Herpes Simplex Virus for glioblastoma treatment.</p> Methods <p>We…
Therapeutic vaccination for glioblastoma elicited by retargeted oncolytic herpes virus
Journal for ImmunoTherapy of Cancer | | Piaggio, F., Riviera, C., Alessandrini, F., Marubbi, D., Ceresa, D., Appolloni, I., Vincenzi, A., Gianni, T., Campadelli-Fiume, G., Malatesta, P.
Topics: brain-cancer, cervical-cancer, immunotherapy, chemotherapy, radiation, research
Read the full article at Journal for ImmunoTherapy of Cancer